Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease
Phase 2
Completed
- Conditions
- Crohn's Disease
- Interventions
- Drug: MT-1303Drug: Placebo
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 78
- Registration Number
- NCT02378688
- Locations
- πΊπ¦
Investigational site, City Name, Ukraine
π©πͺInvestigational Site, City Name, Germany
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 138
- Registration Number
- NCT02354235
- Locations
- π―π΅
Reserch site, Tohoku, Japan
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 154
- Registration Number
- NCT02354222
- Locations
- π―π΅
Reserch site, Tohoku, Japan
Safety Study of MT-4666 in Subjects With Alzheimer's Disease
Phase 3
Terminated
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: MT-4666
- First Posted Date
- 2014-12-30
- Last Posted Date
- 2015-11-13
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 117
- Registration Number
- NCT02327182
- Locations
- π―π΅
Investigational site, Osaka, Kansai, Japan
Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2015-08-20
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 240
- Registration Number
- NCT02314637
- Locations
- π―π΅
Reserch site, Shikoku, Japan
Comparative Oral Bioavailability Study of MT-1303
Phase 1
Completed
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Drug: MT-1303-FormBDrug: MT-1303-FormA
- First Posted Date
- 2014-12-05
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 34
- Registration Number
- NCT02310048
- Locations
- π¬π§
Investigational site, Leeds, United Kingdom
Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients
Phase 1
Completed
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: MT-1303 Low doseDrug: MT-1303 High dose
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 17
- Registration Number
- NCT02307643
- Locations
- π―π΅
Inverstigational site, Tsukuba-shi, Japan
π―π΅Investigational site, Urayasu-shi, Japan
Mass Balance Study of MT-1303
Phase 1
Completed
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Drug: MT-1303
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 8
- Registration Number
- NCT02293967
- Locations
- π¬π§
Investigational site, Ruddington, Nottingham, United Kingdom
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus
Phase 4
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Canagliflozin (TA-7284)Drug: GLP-1 analogue
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2019-04-10
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 71
- Registration Number
- NCT02227849
- Locations
- π―π΅
Reserch site, Kinki, Japan
Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Teneligliptin/Canagliflozin
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 153
- Registration Number
- NCT02220907
- Locations
- π―π΅
Research site, Tohoku, Japan
Β© Copyright 2025. All Rights Reserved by MedPath